BI-D1870 is a small molecule, specific inhibitor of p90 RSK (ribosomal S6 kinase) isoforms RSK1, RSK2, RSK3 and RSK4, both in vitro and in vivo, with IC50s are 31 nM, 24 nM, 18 nM, 15 nM, respectively.

CMK is a RSK2 kinase inhibitor.

Fmk is an irreversible ribosomal S6 kinase inhibitor 1/2 inhibitor.

LJH685 is a selective and potent RSK inhibitor.

LJI308 is a selective and potent RSK inhibitor.

LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.

SC1(Pluripotin) is a sustainer of mES self-renewal and ERK 1 inhibitor

SL 0101-1 is a selective inhibitor of p90 Rsk (ribosomal S6 kinase) (IC50 = 89 nM for Rsk-2).

Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.

RSK4-IN-1 is identified with potent RSK4 inhibitory activity with an IC50 value of 9.5 nM.

PMD-026 (PMD026) is an oral, reversible small molecule inhibitor of ribosomal S6 kinase (RSK1-4) with IC50 of 2 nM (RSK1), 0.7 nM (RSK2), 0.9 nM (RSK3) and 2 nM (RSK4).PMD-026 decreased YB-1 phosphorylation as well as AR V7 mRNA and AR variants expressions in 22Rv1 cells.PMD-026 suppressed cell proliferation alone and in combination with the second-generation antiandrogens enzalutamide and darolutamide by inducing cellular apoptosis and G2/M arrest.PMD-026 suppressed tumor growth, and the combination of PMD-026 and enzalutamide inhibited tumor growth more prominently than single treatment in mouse xenograft models.